Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUR-1100 in Eosinophilic Esophagitis
NCT01386112Phase 2Completed
- Sponsor
- Forest Laboratories
- Start
- Sep 2011
- Primary completion
- Oct 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluticasone propionate in eosinophilic esophagitis (EoE) (3 arms), sponsored by Forest Laboratories. Primary endpoints: Morning serum cortisol (change from baseline) at 8 weeks, Standard safety laboratory tests at 8 weeks and 2 more. Started Sep 2011; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT01386112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386112.